Upgrade to SI Premium - Free Trial

Amgen (AMGN) Reiterated at Neutral by Cantor Fitzgerald Amid Negative/Neutral Sentiment

April 8, 2026 7:41 AM
Cantor Fitzgerald analyst Carter Gould reiterated a Neutral rating and $350.00 price target on Amgen (NASDAQ: AMGN).The analyst commented, "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments